Ensysce Biosciences, listed on Nasdaq, acquired Cy Biopharma, and representatives presented at a public FDA hearing.
8 reports, 2 independent
Updated Thu 00:00
Mostly repetition
Reached 4 outlets in its first 24 hours
- Reports
- 8
- Developments
- 2
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Ensysce Biosciences, listed on Nasdaq, acquired Cy Biopharma, and representatives presented at a public FDA hearing.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Ensysce Biosciences is conducting clinical trials and seeking regulatory feedback from the FDA.1 source
Ensysce announced acquisition of Cy Biopharma and representatives presented at a public FDA hearing.1 source
Keep exploring
The entities involved
Related events
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Two small-cap healthcare companies, Cardiff Oncology and CytomX Therapeutics, are listed on NASDAQ and receive analyst recommendations from MarketBeat.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.